ABBV Analyst Ratings

UBS resumed AbbVie at Neutral ($240) in January. HSBC upgraded to Buy ($265) in December and Scotiabank initiated at Sector Outperform ($280). Consensus is Buy at $306 average target — Humira erosion fears are fading as the immunology pipeline delivers.

ANALYST RATINGS
Buy$239
ABBV
Neutral$240
Resumed
2026-01-07
Buy$265
Upgrade
2025-12-10
Sector Outperform$280
Initiated
2025-11-13
Hold$237
Downgrade
2025-11-04
Buy$270
Upgrade
2025-09-17
Resumed
2026-01-07
UBS
RatingNeutral
From—
Target$240
From—
Upgrade
2025-12-10
HSBC Securities
RatingBuy
FromHold
Target$265
From—
Initiated
2025-11-13
Scotiabank
RatingSector Outperform
From—
Target$280
From—
Downgrade
2025-11-04
DZ Bank
RatingHold
FromBuy
Target$237
From—
Upgrade
2025-09-17
Berenberg
RatingBuy
FromHold
Target$270
From—
Resumed
2025-08-12
Piper Sandler
RatingOverweight
From—
Target$231
From—
Upgrade
2025-08-07
Daiwa Securities
RatingOutperform
FromNeutral
Target$214
From—
Downgrade
2025-05-14
Citigroup
RatingNeutral
FromBuy
Target$205
From—
Initiated
2025-04-22
Cantor Fitzgerald
RatingOverweight
From—
Target$210
From—
Resumed
2024-12-10
BofA Securities
RatingNeutral
From—
Target$191
From—
Downgrade
2024-12-05
Daiwa Securities
RatingNeutral
FromOutperform
Target$180
From—
Upgrade
2024-11-22
Leerink Partners
RatingOutperform
FromMarket Perform
Target$206
From—
Initiated
2024-11-15
Wolfe Research
RatingOutperform
From—
Target$205
From—
Initiated
2024-10-17
Bernstein
RatingMkt Perform
From—
Target$203
From—
Upgrade
2024-06-05
HSBC Securities
RatingBuy
FromHold
Target$185
From—
Initiated
2024-05-17
Cantor Fitzgerald
RatingOverweight
From—
Target$200
From—